PUMA BIOTECHNOLOGY, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$5.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $6.65M, a 36.21% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$11.69M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $12.88M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $5.28M, a 54.72% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $13.15M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$15.82M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$7.58M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$33.06M, a 734.77% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.04M 10-Q · filed 2026-08-06 | $7.83M derived: sum of 3 quarters · filed 2026-08-06 | $13.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$11.69M 10-Q · filed 2026-05-07 | $1.18M derived: sum of 2 quarters · filed 2026-05-07 | $6.46M derived: sum of 3 quarters · filed 2026-05-07 | $11.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.15M derived: sum of 2 quarters · filed 2026-02-26 | $23.04M derived: sum of 3 quarters · filed 2026-08-06 | $13.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.16M derived: sum of 2 quarters · filed 2026-08-06 | $279.00K 10-Q · filed 2025-11-06 | -$13.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.00M 10-Q · filed 2026-08-06 | -$18.76M derived: sum of 3 quarters · filed 2026-08-06 | -$7.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.88M 10-Q · filed 2026-05-07 | -$23.65M derived: sum of 2 quarters · filed 2026-05-07 | -$11.99M derived: sum of 3 quarters · filed 2026-05-07 | -$10.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$13.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.11M derived: sum of 2 quarters · filed 2026-02-26 | -$818.00K derived: sum of 3 quarters · filed 2026-02-26 | -$15.82M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.95M derived: sum of 2 quarters · filed 2025-11-06 | -$2.06M 10-Q · filed 2025-11-06 | $9.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$13.72M 10-Q · filed 2025-08-07 | -$2.39M derived: sum of 3 quarters · filed 2026-02-26 | -$3.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$15.01M 10-Q · filed 2025-05-08 | -$3.67M derived: sum of 2 quarters · filed 2026-02-26 | -$5.23M derived: sum of 3 quarters · filed 2026-02-26 | -$3.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.78M derived: sum of 2 quarters · filed 2026-02-26 | $11.23M derived: sum of 3 quarters · filed 2026-02-26 | -$7.58M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$102.00K derived: sum of 2 quarters · filed 2024-11-07 | -$18.91M 10-Q · filed 2024-11-07 | $1.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$17.36M 10-Q · filed 2024-08-01 | $3.33M derived: sum of 3 quarters · filed 2025-02-27 | $1.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$18.81M 10-Q · filed 2024-05-02 | $1.89M derived: sum of 2 quarters · filed 2025-02-27 | $280.00K derived: sum of 3 quarters · filed 2025-02-27 | -$20.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $19.09M derived: sum of 2 quarters · filed 2025-02-27 | -$2.17M derived: sum of 3 quarters · filed 2025-02-27 | -$33.06M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$22.86M derived: sum of 2 quarters · filed 2023-11-02 | -$53.76M 10-Q · filed 2023-11-02 | -$52.27M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$21.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$52.16M 10-Q · filed 2023-08-03 | -$50.66M derived: sum of 3 quarters · filed 2024-02-29 | -$28.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$30.90M 10-Q · filed 2023-05-04 | -$29.40M derived: sum of 2 quarters · filed 2024-02-29 | -$7.18M derived: sum of 3 quarters · filed 2024-02-29 | -$19.13M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $23.71M derived: sum of 2 quarters · filed 2024-02-29 | $11.77M derived: sum of 3 quarters · filed 2024-02-29 | $5.21M 10-K · filed 2024-02-29 |
| 2021-09-30 | $22.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $10.27M derived: sum of 2 quarters · filed 2022-11-03 | $3.71M 10-Q · filed 2022-11-03 | $2.01M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | -$11.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$18.50M 10-Q · filed 2022-08-04 | -$20.20M derived: sum of 3 quarters · filed 2023-03-02 | $593.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | -$6.56M 10-Q · filed 2022-05-05 | -$8.26M derived: sum of 2 quarters · filed 2023-03-02 | $12.54M derived: sum of 3 quarters · filed 2023-03-02 | $12.26M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $19.10M derived: sum of 2 quarters · filed 2023-03-02 | $18.82M derived: sum of 3 quarters · filed 2023-03-02 | $19.25M 10-K · filed 2023-03-02 |
| 2020-09-30 | $20.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $20.52M derived: sum of 2 quarters · filed 2021-11-04 | $20.95M 10-Q · filed 2021-11-04 | $13.21M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $155.00K 10-Q · filed 2021-08-05 | -$7.59M derived: sum of 3 quarters · filed 2022-03-03 | |
| 2020-03-31 | $434.00K 10-Q · filed 2021-05-06 | -$7.31M derived: sum of 2 quarters · filed 2022-03-03 | ||
| 2019-12-31 | -$7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $22.60M 10-K · filed 2022-03-03 | ||
| 2019-09-30 | $30.34M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $15.78M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |